← All trials
NCT06647862
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 24, 2024
- Primary completion
- Oct 24, 2026
- Completion date
- Oct 24, 2029
- First posted
- Oct 18, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 170
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ImmuneOnco Biopharmaceuticals (Shanghai) Co., LtdLead sponsor
- Zhejiang UniversityOfficial
- Tsinghua UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.